BeyondSpring
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The last earnings update was 24 days ago. More info.
Add to Portfolio Compare Print
- BeyondSpring has significant price volatility in the past 3 months.
BYSI Share Price and Events
7 Day Returns
1 Year Returns
BYSI Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| BeyondSpring (BYSI) | -4.9% | 3.9% | -19.7% | -46.1% | - | - |
| US Biotechs | 1% | -0% | -3.2% | -4.6% | 3.8% | 9.7% |
| US Market | 0.2% | -1.6% | 2.4% | 2.9% | 36.1% | 41% |
1 Year Return vs Industry and Market
- BYSI underperformed the Biotechs industry which returned -4.6% over the past year.
- BYSI underperformed the Market in United States of America which returned 2.9% over the past year.
BYSI Value
Is BeyondSpring undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
In this section, we usually try to help investors determine whether BeyondSpring is trading at an attractive price based on the cash flow it is expected to produce in the future. But as BeyondSpring has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
- It is not possible to calculate the future cash flow value for BeyondSpring. This is due to cash flow or dividend data being unavailable. The share price is $14.5.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for BeyondSpring's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
BeyondSpring's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in USD | $-2.42 |
| NasdaqCM:BYSI Share Price ** | NasdaqCM (2019-05-23) in USD | $14.5 |
| United States of America Biotechs Industry PE Ratio | Median Figure of 35 Publicly-Listed Biotechs Companies | 19.23x |
| United States of America Market PE Ratio | Median Figure of 3,085 Publicly-Listed Companies | 17.79x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of BeyondSpring.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqCM:BYSI Share Price ÷ EPS (both in USD) = 14.5 ÷ -2.42 |
-5.99x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- BeyondSpring is loss making, we can't compare its value to the US Biotechs industry average.
- BeyondSpring is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does
BeyondSpring's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -5.99x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts |
62.9%per year |
| United States of America Biotechs Industry PEG Ratio | Median Figure of 28 Publicly-Listed Biotechs Companies | 1.26x |
| United States of America Market PEG Ratio | Median Figure of 2,123 Publicly-Listed Companies | 1.54x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for BeyondSpring, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
BeyondSpring's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in USD | $-0.33 |
| NasdaqCM:BYSI Share Price * | NasdaqCM (2019-05-23) in USD | $14.5 |
| United States of America Biotechs Industry PB Ratio | Median Figure of 414 Publicly-Listed Biotechs Companies | 3.35x |
| United States of America Market PB Ratio | Median Figure of 5,201 Publicly-Listed Companies | 1.84x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqCM:BYSI Share Price ÷ Book Value per Share (both in USD) = 14.5 ÷ -0.33 |
-43.29x |
* Primary Listing of BeyondSpring.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- BeyondSpring has negative assets, we can't compare the value of its assets to the US Biotechs industry average.
Value checks
We assess BeyondSpring's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) BeyondSpring has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
BYSI Future Performance
How is BeyondSpring expected to perform in the next 1 to 3 years based on estimates from 2 analysts?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- BeyondSpring's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
- BeyondSpring's earnings growth is expected to exceed the United States of America market average.
- Unable to compare BeyondSpring's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NasdaqCM:BYSI Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts | 62.9% |
| United States of America Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 22.6% |
| United States of America Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 17.7% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 13.7% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.3% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 2 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 255 | 117 | 2 | |
| 2022-12-31 | 122 | 20 | 2 | |
| 2021-12-31 | 49 | -39 | 2 | |
| 2020-12-31 | 38 | -39 | 2 | |
| 2019-12-31 | 8 | -58 | 2 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | -40 | -55 | |
| 2018-09-30 | -41 | -56 | |
| 2018-06-30 | -40 | -57 | |
| 2018-03-31 | -32 | -58 | |
| 2017-12-31 | -29 | -92 | |
| 2017-09-30 | -24 | -80 | |
| 2017-06-30 | -19 | -67 | |
| 2017-03-31 | -17 | -58 | |
| 2016-12-31 | -14 | -12 | |
| 2016-09-30 | -11 | -10 | |
| 2016-06-30 | -9 | -9 | |
| 2016-03-31 | -7 | -8 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 2 Analyst Estimates (S&P Global) | See Below |
All data from BeyondSpring Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 3.41 | 6.03 | 0.79 | 2.00 |
| 2022-12-31 | 0.60 | 1.38 | -0.18 | 2.00 |
| 2021-12-31 | -1.18 | -1.16 | -1.19 | 2.00 |
| 2020-12-31 | -1.22 | -0.74 | -1.70 | 2.00 |
| 2019-12-31 | -2.14 | -1.82 | -2.45 | 2.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2018-12-31 | -2.42 |
| 2018-09-30 | -2.49 |
| 2018-06-30 | -2.57 |
| 2018-03-31 | -2.64 |
| 2017-12-31 | -4.40 |
| 2017-09-30 | -4.08 |
| 2017-06-30 | -3.71 |
| 2017-03-31 | -3.47 |
| 2016-12-31 | -0.75 |
| 2016-09-30 | -0.66 |
| 2016-06-30 | -0.57 |
| 2016-03-31 | -0.49 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if BeyondSpring will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess BeyondSpring's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
BeyondSpring has a total score of 3/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
BYSI Past Performance
How has BeyondSpring performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- BeyondSpring does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare BeyondSpring's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare BeyondSpring's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
All data from BeyondSpring Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | -54.87 | 5.93 | 51.62 | |
| 2018-09-30 | -55.84 | 5.86 | 53.05 | |
| 2018-06-30 | -56.85 | 7.29 | 55.06 | |
| 2018-03-31 | -58.02 | 8.74 | 56.26 | |
| 2017-12-31 | -91.76 | 9.05 | 88.93 | |
| 2017-09-30 | -79.81 | 7.68 | 77.25 | |
| 2017-06-30 | -67.36 | 4.88 | 64.70 | |
| 2017-03-31 | -57.56 | 2.55 | 55.70 | |
| 2016-12-31 | -12.01 | 1.93 | 10.44 | |
| 2016-09-30 | -10.49 | 1.80 | 9.15 | |
| 2016-06-30 | -8.99 | 1.56 | 7.67 | |
| 2016-03-31 | -7.63 | 1.34 | 6.12 | |
| 2015-12-31 | -7.97 | 1.19 | 6.28 | |
| 2014-12-31 | -3.01 | 0.23 | 1.88 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if BeyondSpring has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
- It is difficult to establish if BeyondSpring has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if BeyondSpring improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
Past performance checks
We assess BeyondSpring's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
BeyondSpring has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
BYSI Health
How is BeyondSpring's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up BeyondSpring's finances.
The net worth of a company is the difference between its assets and liabilities.
- BeyondSpring's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- BeyondSpring has no long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- BeyondSpring has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from BeyondSpring Company Filings, last reported 4 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | -9.38 | 0.00 | 3.89 |
| 2018-09-30 | -9.38 | 0.00 | 3.89 |
| 2018-06-30 | 19.81 | 0.00 | 22.44 |
| 2018-03-31 | 18.09 | 0.00 | 21.54 |
| 2017-12-31 | 28.04 | 0.00 | 30.56 |
| 2017-09-30 | 40.49 | 0.00 | 40.72 |
| 2017-06-30 | 47.91 | 0.00 | 48.98 |
| 2017-03-31 | 54.03 | 0.00 | 54.56 |
| 2016-12-31 | 12.30 | 0.00 | 11.69 |
| 2016-09-30 | 16.03 | 0.00 | 17.33 |
| 2016-06-30 | 4.03 | 0.00 | 5.63 |
| 2016-03-31 | 9.66 | 0.00 | 10.82 |
| 2015-12-31 | 9.66 | 0.00 | 10.82 |
| 2014-12-31 | -9.39 | 7.83 | 0.39 |
- BeyondSpring has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
- Irrelevant to check if BeyondSpring's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- BeyondSpring has less than a year of cash runway based on current free cash flow.
- BeyondSpring has less than a year of cash runway if free cash flow continues to grow at historical rates of 59% each year.
Financial health checks
We assess BeyondSpring's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) BeyondSpring has a total score of 1/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
BYSI Dividends
What is BeyondSpring's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
BeyondSpring
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate BeyondSpring's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate BeyondSpring's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 2 Analyst Estimates (S&P Global) | See Below |
| Global Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 19 Stocks | 2.4% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2005 Stocks | 2.5% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.4% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | ||
| 2020-12-31 | ||
| 2019-12-31 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as BeyondSpring has not reported any payouts.
- Unable to verify if BeyondSpring's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess BeyondSpring's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can BeyondSpring afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) BeyondSpring has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
BYSI Management
CEO
| AGE | 47 |
| TENURE AS CEO | 4.5 years |
CEO Bio
Dr. Lan Huang, Ph.D., co-founded BeyondSpring Pharmaceuticals, Inc. in 2013 and serves as its Chairman and Chief Executive Officer. Dr. Huang Co-founded BeyondSpring Inc. and has been its Chairman and Chief Executive Officer since November 2014. She has more than a decade of entrepreneurial experience in the Chinese and U.S. biotechnology industry. Prior to founding BeyondSpring, Dr. Huang co-founded Wuxi MTLH Biotechnology Co. Ltd., in 2007, where she served as Chief Executive Officer since 2010 and whose self-designed cancer peptide drug’s China rights were acquired in 2010 by Shanghai Pharmaceutical Group, one of the top three pharmaceutical companies in China. She also co-founded Paramax International in 2008, which was sold to RPS (a global CRO), then to Warburg Pincus in 2011. In 2010, Dr. Huang founded Wanchun Biotech. Her translational research in cancer signaling pathways involving Ras was published in two Nature papers. In addition, Dr. Huang worked with Forward Ventures, where she led partnering initiatives between Forward’s portfolio companies and Chinese pharmaceutical companies. Dr. Huang was trained at Memorial Sloan Kettering Cancer Center from 1998 to 2002, where her breakthrough research in solving the first E2-E3 ubiquitin ligase structure involving P53 degradation was published in Science following 10 months of preparation. She serves as Director of Wuxi MTLH Biotechnology Co. Ltd. The immense importance of this field is illustrated by the 2005 award of the Nobel Prize in Chemistry to the founders of ubiquitin-mediated protein degradation. She has invented and holds patents for a number of biotech products for oncology and dermatology indications. In 2009, she was the recipient of China’s “Thousand Talent Innovator Award.” She received her Ph.D. in Chemistry in four-and-a-half years from the University of California at Berkeley, where she won the graduating Ph.D. woman award from Soroptimist International. Her translational research in cancer signaling pathways involving Ras was published in two Nature papers. Dr. Huang received her B.A., Magna Cum Laude and Phi Beta Kappa, from Lawrence University, where she served as a trustee from 2012 to 2015. She also studied at Fudan University in Shanghai, China.
CEO Compensation
- Insufficient data for Lan to compare compensation growth.
- Insufficient data for Lan to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the BeyondSpring management team in years:
- The average tenure for the BeyondSpring management team is less than 2 years, this suggests a new team.
Management Team
Lan Huang
Co-Founder
47
4.5 yrs
Edward Liu
Chief Financial Officer
36
1.2 yrs
Rich Daly
Chief Operating Officer
57
0.8 yrs
Ramon Mohanlal
Executive VP of Research & Development and Chief Medical Officer
60
G. Lloyd
Chief Scientific Officer
74
Gordon Schooley
Chief Regulatory Officer
71
Christine Zhao
Director
46
2.6 yrs
James Tonra
Senior Vice President of Preclinical Development
52
1.1 yrs
Amy Yang
Controller
Board of Directors Tenure
Average tenure and age of the BeyondSpring board of directors in years:
- The tenure for the BeyondSpring board of directors is about average.
Board of Directors
Lan Huang
Co-Founder
47
4.5 yrs
Matthew Kirkby
Director
49
2.6 yrs
Pat Fabbio
Independent Director
50
1.3 yrs
Quanqi Song
Director
53
3 yrs
Yanbin Xie
Director
60
3 yrs
Douglas Blayney
Member of Scientific Advisors & Principal Investigators Board
68
Jeffrey Crawford
Member of Scientific Advisors & Principal Investigators Board
Yuankai Shi
Member of Scientific Advisors & Principal Investigators Board
David Ettinger
Member of Scientific Advisors & Principal Investigators Board
Yan Sun
Member of Scientific Advisors & Principal Investigators Board
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
Management checks
We assess BeyondSpring's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) BeyondSpring has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
BYSI News
Simply Wall St News
Loss-Making BeyondSpring Inc. (NASDAQ:BYSI) Expected To Breakeven
BeyondSpring Inc.'s (NASDAQ:BYSI):. … With the latest financial year loss of -US$91.8m and a trailing-twelve month of -US$56.8m, the US$377m market-cap alleviates its loss by moving closer towards its target of breakeven? … Consensus from the 2 Biotechs analysts is BYSI is on the verge of breakeven.
Simply Wall St - – Full articleDo Directors Own BeyondSpring Inc. (NASDAQ:BYSI) Shares?
(NASDAQ:BYSI) should be aware of the most powerful shareholder groups. … Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. … Taking a look at our data on the ownership groups (below), it's seems that.
Simply Wall St - – Full articleMarket Sentiment Around Loss-Making BeyondSpring Inc (NASDAQ:BYSI)
The US$480m market-cap posted a loss in its most recent financial year of -US$91.8m and a latest trailing-twelve-month loss of -US$56.8m shrinking the gap between loss and breakeven. … I’ve put together a brief outline of industry analyst expectations for BYSI, its year of breakeven and its implied growth rate … Expectation from Biotechs analysts is BYSI is on the verge of breakeven.
Simply Wall St - – Full articleWhen Will BeyondSpring Inc (NASDAQ:BYSI) Turn A Profit?
BeyondSpring Inc's (NASDAQ:BYSI):. … With the latest financial year loss of -US$91.76m and a trailing-twelve month of -US$58.02m, the US$628.04m market-cap alleviates its loss by moving closer towards its target of breakeven. … I’ve put together a brief outline of industry analyst expectations for BYSI, its year of breakeven and its implied growth rate
Simply Wall St - – Full articleBeyondSpring Inc (NASDAQ:BYSI): Are Analysts Optimistic?
View our latest analysis for BeyondSpring BYSI is bordering on breakeven, according to analysts. … BYSI is therefore projected to breakeven around 2 years from today. … For a more comprehensive look at BYSI, take a look at BYSI’s company page on Simply Wall St.
Simply Wall St - – Full articleBYSI Company Info
Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab. BeyondSpring Inc. was founded in 2010 and is headquartered in New York, New York.
Details
| Name: | BeyondSpring Inc. |
| BYSI | |
| Exchange: | NasdaqCM |
| Founded: | 2010 |
| $336,176,874 | |
| 23,184,612 | |
| Website: | http://www.beyondspringpharma.com |
| Address: |
BeyondSpring Inc. 28 Liberty Street, 39th Floor, New York, New York, 10005, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqCM | BYSI | Ordinary Shares | Nasdaq Capital Market | US | USD | 09. Mar 2017 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/05/24 00:49 |
| End of day share price update: | 2019/05/23 00:00 |
| Last estimates confirmation: | 2019/04/30 |
| Last earnings filing: | 2019/04/30 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
